Holen Sie sich die Stockscreener-App
0.3602
10.08%
-0.0404
Handel nachbörslich:
.37
0.0098
+2.72%
Schlusskurs vom Vortag:
$0.4006
Offen:
$0.3967
24-Stunden-Volumen:
1.75M
Relative Volume:
1.03
Marktkapitalisierung:
$21.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.1391
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
-32.57%
1M Leistung:
-55.27%
6M Leistung:
-7.12%
1J Leistung:
-35.68%
1-Tages-Spanne:
$0.36
$0.4099
1-Wochen-Bereich:
$0.36
$0.5684
52-Wochen-Spanne:
$0.2601
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Vergleichen Sie BCAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3602 | 23.55M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
Is BioAtla Inc. stock attractive for hedge funds2025 Volatility Report & Daily Stock Trend Reports - ulpravda.ru
Is BioAtla Inc. stock dividend yield sustainable2025 Stock Rankings & Entry Point Confirmation Alerts - ulpravda.ru
Why BioAtla Inc. stock remains resilientJuly 2025 Gainers & Real-Time Buy Signal Notifications - ulpravda.ru
What risks investors should watch in BioAtla Inc. stockEarnings Risk Report & Fast Entry Momentum Trade Alerts - ulpravda.ru
How BioAtla Inc. stock performs in rising dollar environmentMarket Volume Summary & Short-Term Trading Alerts - ulpravda.ru
Will BioAtla Inc. stock maintain momentum in 20252026 world cup usa national team round of 16 defensive leaders possession football winner prediction guide - ulpravda.ru
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla, GATC Health Advance Ozuriftamab Vedotin Into Phase 3 OPSCC Trial Via SPV Deal - Voice Of HealthCare
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Asianet Newsable
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
BioAtla’s Phase 3 Cancer Trial Is “AI-Backed”. Just Not in the Way You Think - AIM Media House
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Australia
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
Bioatla stock rises after $40 million SPV deal to advance cancer drug By Investing.com - Investing.com South Africa
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com India
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla Secures $5 Million Initial Funding for Phase 3 Trial of Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma - Quiver Quantitative
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$40M AI-driven cancer deal backs new OPSCC drug into Phase 3 test - Stock Titan
BioAtla adjourns special meeting, stockholders approve share issuance By Investing.com - Investing.com Australia
BioAtla Stockholders Approve Share Issuance, Delay Reverse Split - TipRanks
BioAtla adjourns special meeting, stockholders approve share issuance - Investing.com India
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - Defense World
Can BioAtla Inc. stock reach $100 price targetGap Up & Safe Swing Trade Setup Alerts - Улправда
Aug Drivers: Why retail investors pile into BioAtla Inc. stockInsider Selling & Weekly Watchlist of Top Performers - Улправда
Why retail investors pile into BioAtla Inc. stockTrade Volume Report & Technical Pattern Alert System - Улправда
How rising interest rates impact BioAtla Inc. stock2025 Bull vs Bear & Weekly Momentum Stock Picks - DonanımHaber
Can BioAtla Inc. stock rebound after recent weakness2025 Analyst Calls & Verified Stock Trade Ideas - Улправда
Can BioAtla Inc. stock resist market sell offsEarnings Overview Report & Daily Entry Point Alerts - Улправда
BioAtla Earnings Notes - Trefis
Acorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB - Defense World
What drives BioAtla Inc stock priceIndustrial Stocks Review & Exceptional Capital Trading - earlytimes.in
Taking on analysts’ expectations and winning: BioAtla Inc (BCAB) - setenews.com
BioAtla (NASDAQ: BCAB) seeks approval for stock issuance and reverse split - Stock Titan
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):